


## PHARMACEUTICAL 2021

## UroGen Pharma Ltd. Rank 353 of 409







## PHARMACEUTICAL 2021

## UroGen Pharma Ltd. Rank 353 of 409



The relative strengths and weaknesses of UroGen Pharma Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UroGen Pharma Ltd. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 45% points. The greatest weakness of UroGen Pharma Ltd. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 300% points.

The company's Economic Capital Ratio, given in the ranking table, is -563%, being 208% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	115,619
Cost of Goods Sold	1,009
Intangible Assets	0
Liabilities, Current	21,436
Liabilities, Non-Current	1,497
Other Assets	4,340
Other Compr. Net Income	-5.0
Other Expenses	3,374
Other Liabilities	2,717
Other Net Income	1,629
Property and Equipment	2,046
Research and Development	47,310
Revenues	11,799
Selling, General and Administrative Expense	90,219

Output Variable	Value in 1000 USD
Assets	122,005
Liabilities	25,650
Expenses	141,912
Stockholders Equity	96,355
Net Income	-128,484
Comprehensive Net Income	-128,486
Economic Capital Ratio	-563%